CDH VGC

CDH VGC was founded in 2015 as part of CDH Investments. It focuses on investing in technological innovation with social impact across healthcare, artificial intelligence & technology, consumer goods, and enterprise solutions. In healthcare/biotech specifically, it has invested in over 90 innovative industry leaders including GemPharmatech—the world’s largest provider of genetically modified mouse models used globally for research and drug development. The fund leverages both venture capital and growth equity strategies to identify high-potential projects that can drive industry evolution.

Example Portfolio Highlight: GemPharmatech—backed by CDH VGC—has created over 20,000+ genetically engineered mouse models (GEMMs), supporting global pharmaceutical R&D efforts. GemPharmatech completed its IPO on Shanghai’s Science and Technology Innovation Board in April 2022.